ATNM Quote, Trading Chart, Actinium Pharmaceuticals Inc.
home / stock / atnm / atnm quote
$5.63 Last:
2.36% Change Percent:
$5.5 Open:
$5.63 Previous Close:
$5.63 High:
$5.32 Low:
219,625 Volume:
05/27/2022 04:56:09 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
ATNM Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-05-27 | 5.5 | 5.63 | 5.63 | 5.32 | 219,625 |
| 2022-05-26 | 5.55 | 5.5 | 5.7432 | 5.45 | 192,178 |
| 2022-05-25 | 5.57 | 5.56 | 5.6371 | 5.41 | 140,364 |
| 2022-05-24 | 5.82 | 5.57 | 5.89 | 5.5193 | 178,526 |
| 2022-05-23 | 6.11 | 5.92 | 6.11 | 5.8362 | 117,572 |
| 2022-05-20 | 6.12 | 6.05 | 6.18 | 5.77 | 228,990 |
| 2022-05-19 | 5.92 | 6.08 | 6.34 | 5.92 | 202,675 |
| 2022-05-18 | 6.17 | 6.03 | 6.2409 | 5.9 | 132,176 |
| 2022-05-17 | 5.88 | 6.2 | 6.27 | 5.7701 | 260,892 |
| 2022-05-16 | 5.41 | 5.74 | 6 | 5.38 | 238,916 |
| 2022-05-13 | 5.63 | 5.75 | 5.83 | 5.32 | 548,437 |
| 2022-05-12 | 5.22 | 5.51 | 5.55 | 5.14 | 467,040 |
| 2022-05-11 | 5.35 | 5.15 | 5.45 | 5.09 | 349,956 |
| 2022-05-10 | 5.59 | 5.38 | 5.73 | 5.21 | 451,160 |
| 2022-05-09 | 5.67 | 5.52 | 5.815 | 5.43 | 416,099 |
| 2022-05-06 | 5.99 | 5.72 | 6.1 | 5.7 | 260,709 |
| 2022-05-05 | 6.13 | 6.01 | 6.1617 | 5.87 | 240,256 |
| 2022-05-04 | 6.4 | 6.29 | 6.4 | 5.98 | 173,061 |
| 2022-05-03 | 6.04 | 6.4 | 6.44 | 5.87 | 248,091 |
| 2022-05-02 | 5.9 | 6.05 | 6.19 | 5.8115 | 271,567 |
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
News, Short Squeeze, Breakout and More Instantly...
-
Actinium Pharmaceuticals (ATNM) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>
-
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cell...
-
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation &a...